Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BG, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG (2021)

Publication Type: Journal article, Review article

Publication year: 2021

Journal

Book Volume: 22

Pages Range: e105-e118

Journal Issue: 3

DOI: 10.1016/S1470-2045(20)30756-7

Abstract

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

Involved external institutions

Wiener Gesundheitsverbund Kliniken Austria (AT) Translational Genomics Research Institute (TGen) United States (USA) (US) Oslo University Hospital / Oslo Universitetssykehus Rikshospitalet Norway (NO) UCSF Medical Center United States (USA) (US) University College London (UCL) United Kingdom (GB) Cedars-Sinai Medical Center United States (USA) (US) Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille) France (FR) Jagiellonian University Medical College Poland (PL) Stanford University United States (USA) (US) Massachusetts General Hospital United States (USA) (US) Vrije Universiteit Amsterdam (VU) / University Amsterdam Netherlands (NL) Emory University United States (USA) (US) University of Bologna / Università di Bologna Italy (IT) University of Iceland (UI) / Háskóli Íslands Iceland (IS) Columbia University United States (USA) (US) University Hospital Ostrava / Fakultní Nemocnice Ostrava Czech Republic (CZ) Kantonsspital St.Gallen Switzerland (CH) Hospital Clínic de Barcelona Spain (ES) Centre hospitalier universitaire de Poitiers (CHU de Poitiers) France (FR) University of the Republic / Universidad de la República (UdelaR) Uruguay (UY) Mayo Clinic in Arizona United States (USA) (US) Shanghai Changzheng Hospital China (CN) National University of Singapore (NUS) Singapore (SG) Southern Älvsborg Hospital / Södra Älvsborgs sjukhus (SÄS) Sweden (SE) Poznan University of Medical Sciences / Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Poland (PL) Nantes University Hospital / Centre hospitalier universitaire de Nantes (CHU) France (FR) Universitätsklinikum Heidelberg Germany (DE) Dana–Farber Cancer Institute United States (USA) (US) Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino Italy (IT) Ankara University / Ankara Üniversitesi Turkey (TR) Levine Cancer Institute United States (USA) (US) The Institute of Cancer Research (ICR) United Kingdom (GB) Medical College of Wisconsin (MCW) United States (USA) (US) Mayo Clinic United States (USA) (US) Universidad de Navarra Spain (ES) New York University (NYU) United States (USA) (US) University of Calgary Canada (CA) Champalimaud Foundation / Fundação Champalimaud Portugal (PT) Universitätsklinikum Würzburg Germany (DE) Erasmus University Medical Center (MC) Netherlands (NL) Albert-Ludwigs-Universität Freiburg Germany (DE) University of Copenhagen Denmark (DK) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) H. Lee Moffitt Cancer Center & Research Institute United States (USA) (US) Clinica São Germano Brazil (BR) Sarah Cannon Research Institute (SCRI) United States (USA) (US) O'Neal Comprehensive Cancer Center at UAB United States (USA) (US) Universidade Federal do Rio de Janeiro (UFRJ) / Federal University of Rio de Janeiro Brazil (BR) St. Olavs University Hospital / St. Olavs Hospital Universitetssykehuset i Trondheim Norway (NO) Hackensack Meridian Health United States (USA) (US) Marqués de Valdecilla University Hospital / Hospital Universitario de Marqués de Valdecilla (HUMV) Spain (ES) The University of Melbourne Australia (AU) University of Nebraska Medical Center (UNMC) United States (USA) (US) Memorial Hospitals Group Turkey (TR) Peter MacCallum Cancer Centre Australia (AU) Karolinska University Hospital / Karolinska Universitetssjukhuset Sweden (SE) St James's University Hospital United Kingdom (GB) Complejo Hospitalario de Salamanca / Complejo Asistencial Universitario de Salamanca Spain (ES)

How to cite

APA:

Moreau, P., Kumar, S.K., San Miguel, J., Davies, F., Zamagni, E., Bahlis, N.,... Richardson, P.G. (2021). Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, 22(3), e105-e118. https://doi.org/10.1016/S1470-2045(20)30756-7

MLA:

Moreau, Philippe, et al. "Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group." Lancet Oncology 22.3 (2021): e105-e118.

BibTeX: Download